Effects of HIV and Methamphetamine on Brain and Behavior: Evidence from Human Studies and Animal Models

Journal of Neuroimmune Pharmacology

Volumn 11, Issue 3, 2016, Pages 495-510

  Soontornniyomkij, Virawudh ^a   Kesby, James P ^a,b   Morgan, Erin E ^a   Bischoff Grethe, Amanda ^a   Minassian, Arpi ^a   Brown, Gregory G ^a   Grant, Igor ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c TMARC) Group

Author keywords

Cognition; gp120; Inhibition; Neuroimaging; Neuropathology; Tat

Indexed keywords

ESTROGEN; GLYCOPROTEIN GP 120; METHAMPHETAMINE; VIRUS RNA;

BEHAVIOR DISORDER; COGNITIVE DEFECT; DENDRITE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICATION COMPLIANCE; NERVOUS SYSTEM INJURY; NEUROANATOMY; NEUROIMAGING; NEUROPATHOLOGY; NEUROTOXICITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SEROCONVERSION; SOCIAL COGNITION; STEREOTYPIC BEHAVIOR; WHITE MATTER; AMPHETAMINE-RELATED DISORDERS; ANIMAL; ANIMAL BEHAVIOR; BRAIN; CHEMICALLY INDUCED; COGNITION DISORDERS; DIAGNOSTIC IMAGING; DISEASE MODEL; DRUG EFFECTS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PSYCHOLOGY; SOCIAL BEHAVIOR DISORDERS;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HUMANS; METHAMPHETAMINE; SOCIAL BEHAVIOR DISORDERS;

EID: 84982273141     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-016-9699-0     Document Type: Review

References (146)

1. Al-Harthi L (2012) Interplay between Wnt/β-catenin signaling and HIV: virologic and biologic consequences in the CNS. J NeuroImmune Pharmacol 7:731–739
2. Anthony IC, Arango JC, Stephens B, Simmonds P, Bell JE (2008) The effects of illicit drugs on the HIV infected brain. Front Biosci 13:1294–1307
3. Antinori A, Arendt G, Becker JT, et al. (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789–1799
4. Barker GR, Warburton EC (2011) When is the hippocampus involved in recognition memory? J Neurosci 31:10721–10731
5. Barker GR, Bird F, Alexander V, Warburton EC (2007) Recognition memory for objects, place, and temporal order: a disconnection analysis of the role of the medial prefrontal cortex and perirhinal cortex. J Neurosci 27:2948–2957
6. Baron-Cohen S, Wheelwright S, Hill J, Raste Y, Plumb I (2001) The "reading the mind in the eyes" test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry 42:241–251
7. Bechara A, Damasio AR (2005) The somatic marker hypothesis: a neural theory of economic decision. Game Econ Behav 52:336–372
8. Bhaskaran K, Mussini C, Antinori A, Walker AS, Dorrucci M, Sabin C, Phillips A, Porter K (2008) Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 63:213–221
9. Blackstone K, Iudicello JE, Morgan EE, Weber E, Moore DJ, Franklin DR, Ellis RJ, Grant I, Woods SP (2013) Human immunodeficiency virus infection heightens concurrent risk of functional dependence in persons with long-term methamphetamine use. J Addict Med 7:255–263
10. Bonnet F, Amieva H, Marquant F, Bernard C, Bruyand M, Dauchy FA, Mercié P, Greib C, Richert L, Neau D, Catheline G, Dehail P, Dabis F, Morlat P, Dartigues JF, Chêne G (2013) Cognitive disorders in HIV-infected patients: are they HIV-related? AIDS 27:391–400
11. Borgmann K, Ghorpade A (2015) HIV-1, methamphetamine and astrocytes at neuroinflammatory crossroads. Front Microbiol 6:1143
12. Bortell N, Morsey B, Basova L, Fox HS, Marcondes MC (2015) Phenotypic changes in the brain of SIV-infected macaques exposed to methamphetamine parallel macrophage activation patterns induced by the common gamma-chain cytokine system. Front Microbiol 6:900
13. Buckner CM, Calderon TM, Willams DW, Belbin TJ, Berman JW (2011) Characterization of monocyte maturation/differentiation that facilitates their transmigration across the blood-brain barrier and infection by HIV: implications for NeuroAIDS. Cell Immunol 267:109–123
14. Cadet JL, Krasnova IN (2007) Interactions of HIV and methamphetamine: cellular and molecular mechanisms of toxicity potentiation. Neurotox Res 12:181–204
15. Cadet JL, Krasnova IN (2009) Molecular bases of methamphetamine-induced neurodegeneration. Int Rev Neurobiol 88:101–119
16. Carey CL, Woods SP, Rippeth JD, Gonzalez R, Heaton RK, Grant I (2006) Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection. AIDS Behav 10:185–190
17. Carey AN, Sypek EI, Singh HD, Kaufman MJ, McLaughlin JP (2012) Expression of HIV-tat protein is associated with learning and memory deficits in the mouse. Behav Brain Res 229:48–56
18. Center for Behavioral Health Statistics and Quality (2015) Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health. In: HHS Publication No. SMA 15–4927, NSDUH Series H-50. Retrieved from http://www.samhsa.gov/data/
19. Centers for Disease Control and Prevention (2014) HIV Surveillance Report. In: http://www.cdc.gov/hiv/library/reports/surveillance/, November 2015 Edition
20. Chana G, Everall IP, Crews L, Langford D, Adame A, Grant I, Cherner M, Lazzaretto D, Heaton R, Ellis R, Masliah E (2006) Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users. Neurology 67:1486–1489
21. Chang L, Ernst T, Speck O, Grob CS (2005) Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am J Psychiatry 162:361–369
22. Cho AK, Melega WP (2002) Patterns of methamphetamine abuse and their consequences. J Addict Dis 21:21–34
23. Cisneros IE, Ghorpade A (2012) HIV-1, methamphetamine and astrocyte glutamate regulation: combined Excitotoxic implications for neuro-AIDS. Curr HIV Res 10:392–406
24. Clark KH, Wiley CA, Bradberry CW (2013) Psychostimulant abuse and neuroinflammation: emerging evidence of their interconnection. Neurotox Res 23:174–188
25. Coley JS, Calderon TM, Gaskill PJ, Eugenin EA, Berman JW (2015) Dopamine increases CD14 + CD16+ monocyte migration and adhesion in the context of substance abuse and HIV neuropathogenesis. PLoS One 10:e0117450
26. Colfax G, Shoptaw S (2005) The methamphetamine epidemic: implications for HIV prevention and treatment. Curr HIV/AIDS Rep 2:194–199
27. Connolly CG, Bischoff-Grethe A, Jordan SJ, Woods SP, Ellis RJ, Paulus MP, Grant I, Translational Methamphetamine AIDS Research Center Group (2014) Altered functional response to risky choice in HIV infection. PLoS One 9:e111583
28. Crews L, Lentz MR, Gonzalez RG, Fox HS, Masliah E (2008) Neuronal injury in simian immunodeficiency virus and other animal models of neuroAIDS. J Neurovirol 14:327–339
29. Cysique LA, Brew BJ (2009) Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review. Neuropsychol Rev 19:169–185
30. Desplats P, Dumaop W, Cronin P, Gianella S, Woods S, Letendre S, Smith D, Masliah E, Grant I (2014) Epigenetic alterations in the brain associated with HIV-1 infection and methamphetamine dependence. PLoS One 9:e102555
31. Di Chiara G, Bassareo V (2007) Reward system and addiction: what dopamine does and doesn’t do. Curr Opin Pharmacol 7:69–76
32. Dluzen DE, Tweed C, Anderson LI, Laping NJ (2003) Gender differences in methamphetamine-induced mRNA associated with neurodegeneration in the mouse nigrostriatal dopaminergic system. Neuroendocrinology 77:232–238
33. Doyle KL, Morgan EE, Morris S, Smith DM, Little S, Iudicello JE, Blackstone K, Moore DJ, Grant I, Letendre SL, Woods SP (2013) Real-world impact of neurocognitive deficits in acute and early HIV infection. J Neurovirol 19:565–573
34. Ellery PJ, Tippett E, Chiu YL, Paukovics G, Cameron PU, Solomon A, Lewin SR, Gorry PR, Jaworowski A, Greene WC, Sonza S, Crowe SM (2007) The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol 178:6581–6589
35. Ellis RJ, Childers ME, Cherner M, Lazzaretto D, Letendre S, Grant I, HIV Neurobehavioral Research Center Group (2003) Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy. J Infect Dis 188:1820–1826
36. Everall I, Salaria S, Roberts E, Corbeil J, Sasik R, Fox H, Grant I, Masliah E (2005) Methamphetamine stimulates interferon inducible genes in HIV infected brain. J Neuroimmunol 170:158–171
37. Fama R, Rosenbloom MJ, Sassoon SA, Thompson MA, Pfefferbaum A, Sullivan EV (2011) Remote semantic memory for public figures in HIV infection, alcoholism, and their comorbidity. Alcohol Clin Exp Res 35:265–276
38. Feldman MB, Thomas JA, Alexy ER, Irvine MK (2015) Crystal methamphetamine use and HIV medical outcomes among HIV-infected men who have sex with men accessing support services in New York. Drug Alcohol Depend 147:266–271
39. Fischer-Smith T, Bell C, Croul S, Lewis M, Rappaport J (2008) Monocyte/macrophage trafficking in acquired immunodeficiency syndrome encephalitis: lessons from human and nonhuman primate studies. J Neurovirol 14:318–326
40. Fitting S, Ignatowska-Jankowska BM, Bull C, Skoff RP, Lichtman AH, Wise LE, Fox MA, Su J, Medina AE, Krahe TE, Knapp PE, Guido W, Hauser KF (2013) Synaptic dysfunction in the hippocampus accompanies learning and memory deficits in human immunodeficiency virus type-1 tat transgenic mice. Biol Psychiatry 73:443–453
41. Fowler JS, Volkow ND, Logan J, Alexoff D, Telang F, Wang GJ, Wong C, Ma Y, Kriplani A, Pradhan K, Schlyer D, Jayne M, Hubbard B, Carter P, Warner D, King P, Shea C, Xu Y, Muench L, Apelskog K (2008) Fast uptake and long-lasting binding of methamphetamine in the human brain: comparison with cocaine. NeuroImage 43:756–763
42. Fox HS, Gendelman HE (2012) Commentary: animal models of neuroAIDS. J NeuroImmune Pharmacol 7:301–305
43. Frank MG, Adhikary S, Sobesky JL, Weber MD, Watkins LR, Maier SF (2016) The danger-associated molecular pattern HMGB1 mediates the neuroinflammatory effects of methamphetamine. Brain Behav Immun 51:99–108
44. Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C, Pillay D, Hill T, Johnson M, Gilson R, Anderson J, Easterbrook P, Bansi L, Orkin C, Ainsworth J, Phillips AN, Sabin CA (2011) HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol 18:527–534
45. Gaskill PJ, Calderon TM, Luers AJ, Eugenin EA, Javitch JA, Berman JW (2009) Human immunodeficiency virus (HIV) infection of human macrophages is increased by dopamine: a bridge between HIV-associated neurologic disorders and drug abuse. Am J Pathol 175:1148–1159
46. Gaskill PJ, Carvallo L, Eugenin EA, Berman JW (2012) Characterization and function of the human macrophage dopaminergic system: implications for CNS disease and drug abuse. J Neuroinflammation 9:203
47. Gaskill PJ, Calderon TM, Coley JS, Berman JW (2013) Drug induced increases in CNS dopamine alter monocyte, macrophage and T cell functions: implications for HAND. J NeuroImmune Pharmacol 8:621–642
48. Gonzales R, Mooney L, Rawson RA (2010) The methamphetamine problem in the United States. Annu Rev Public Health 31:385–398
49. Gonzalez R, Bechara A, Martin EM (2007) Executive functions among individuals with methamphetamine or alcohol as drugs of choice: preliminary observations. J Clin Exp Neuropsychol 29:155–159
50. Gorantla S, Makarov E, Finke-Dwyer J, Castanedo A, Holguin A, Gebhart CL, Gendelman HE, Poluektova L (2010) Links between progressive HIV-1 infection of humanized mice and viral neuropathogenesis. Am J Pathol 177:2938–2949
51. Gorantla S, Poluektova L, Gendelman HE (2012) Rodent models for HIV-associated neurocognitive disorders. Trends Neurosci 35:197–208
52. Green MF, Penn DL, Bentall R, Carpenter WT, Gaebel W, Gur RC, Kring AM, Park S, Silverstein SM, Heinssen R (2008) Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull 34:1211–1220
53. Halkitis PN, Levy MD, Solomon TM (2016) Temporal relations between methamphetamine use and HIV seroconversion in gay, bisexual, and other men who have sex with men. J Health Psychol 21:93–99
54. Heaton RK, Clifford DB, Franklin DR, et al. (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 75:2087–2096
55. Heaton RK, Franklin DR, Ellis RJ, et al. (2011) HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 17:3–16
56. Henderson LJ, Sharma A, Monaco MC, Major EO, Al-Harthi L (2012) Human immunodeficiency virus type 1 (HIV-1) transactivator of transcription through its intact core and cysteine-rich domains inhibits Wnt/β-catenin signaling in astrocytes: relevance to HIV neuropathogenesis. J Neurosci 32:16306–16313
57. Henry BL, Minassian A, van Rhenen M, Young JW, Geyer MA, Perry W (2011) Effect of methamphetamine dependence on inhibitory deficits in a novel human open-field paradigm. Psychopharmacology 215:697–707
58. Henry BL, Geyer MA, Buell M, Perry W, Young JW, Minassian A, Translational Methamphetamine AIDS Research Center Group (2013) Behavioral effects of chronic methamphetamine treatment in HIV-1 gp120 transgenic mice. Behav Brain Res 236:210–220
59. Henry BL, Geyer MA, Buell MR, Perry W, Young JW, Minassian A (2014) Prepulse inhibition in HIV-1 gp120 transgenic mice after withdrawal from chronic methamphetamine. Behav Pharmacol 25:12–22
60. Hoare J, Fouche JP, Spottiswoode B, Sorsdahl K, Combrinck M, Stein DJ, Paul RH, Joska JA (2011) White-matter damage in clade C HIV-positive subjects: a diffusion tensor imaging study. J Neuropsychiatry Clin Neurosci 23:308–315
61. Hoare J, Westgarth-Taylor J, Fouche JP, Spottiswoode B, Paul R, Thomas K, Stein D, Joska J (2012) A diffusion tensor imaging and neuropsychological study of prospective memory impairment in south African HIV positive individuals. Metab Brain Dis 27:289–297
62. Hoefer MM, Sanchez AB, Maung R, de Rozieres CM, Catalan IC, Dowling CC, Thaney VE, Pina-Crespo J, Zhang D, Roberts AJ, Kaul M (2015) Combination of methamphetamine and HIV-1 gp120 causes distinct long-term alterations of behavior, gene expression, and injury in the central nervous system. Exp Neurol 263:221–234
63. Hoenigl M, Chaillon A, Moore DJ, Morris SR, Smith DM, Little SJ (2016) Clear links between starting methamphetamine and increasing sexual risk behavior: a cohort study among men who have sex with men. J Acquir Immune Defic Syndr 71:551–557
64. Homer BD, Solomon TM, Moeller RW, Mascia A, DeRaleau L, Halkitis PN (2008) Methamphetamine abuse and impairment of social functioning: a review of the underlying neurophysiological causes and behavioral implications. Psychol Bull 134:301–310
65. Homer BD, Halkitis PN, Moeller RW, Solomon TM (2013) Methamphetamine use and HIV in relation to social cognition. J Health Psychol 18:900–910
66. Huitron-Resendiz S, Henriksen SJ, Barr MC, Testa MP, Crawford E, Parsons LH, Sanchez-Alavez M, Phillips TR (2010) Methamphetamine and lentivirus interactions: reciprocal enhancement of central nervous system disease. J Neurovirol 16:268–278
67. Ipser JC, Brown GG, Bischoff-Grethe A, Connolly CG, Ellis RJ, Heaton RK, Grant I, Translational Methamphetamine AIDS Research Center Group (2015) HIV infection is associated with attenuated frontostriatal intrinsic connectivity: a preliminary study. J Int Neuropsychol Soc 21:203–213
68. Iudicello JE, Morgan EE, Gongvatana A, Letendre SL, Grant I, Woods SP (2014) Detrimental impact of remote methamphetamine dependence on neurocognitive and everyday functioning in older but not younger HIV+ adults: evidence for a legacy effect? J Neurovirol 20:85–98
69. Jernigan TL, Gamst AC, Archibald SL, Fennema-Notestine C, Mindt MR, Marcotte TD, Marcotte TL, Heaton RK, Ellis RJ, Grant I (2005) Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am J Psychiatry 162:1461–1472
70. Jones GJ, Barsby NL, Cohen EA, Holden J, Harris K, Dickie P, Jhamandas J, Power C (2007) HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. J Neurosci 27:3703–3711
71. Kalasinsky KS, Bosy TZ, Schmunk GA, Reiber G, Anthony RM, Furukawa Y, Guttman M, Kish SJ (2001) Regional distribution of methamphetamine in autopsied brain of chronic human methamphetamine users. Forensic Sci Int 116:163–169
72. Kesby JP, Hubbard DT, Markou A, Semenova S (2014) Expression of HIV gp120 protein increases sensitivity to the rewarding properties of methamphetamine in mice. Addict Biol 19:593–605
73. Kesby JP, Markou A, Semenova S (2015a) Cognitive deficits associated with combined HIV gp120 expression and chronic methamphetamine exposure in mice. Eur Neuropsychopharmacol 25:141–150
74. Kesby JP, Heaton RK, Young JW, Umlauf A, Woods SP, Letendre SL, Markou A, Grant I, Semenova S (2015b) Methamphetamine exposure combined with HIV-1 disease or gp120 expression: comparison of learning and executive functions in humans and mice. Neuropsychopharmacology 40:1899–1909
75. Kesby JP, Markou A, Semenova S (2016a) The effects of HIV-1 regulatory TAT protein expression on brain reward function, response to psychostimulants and delay-dependent memory in mice. Neuropharmacology. doi:10.1016/j.neuropharm.2016.06.011
76. Kesby JP, Markou A, Semenova S, Group T (2016b) Effects of HIV/TAT protein expression and chronic selegiline treatment on spatial memory, reversal learning and neurotransmitter levels in mice. Behav Brain Res 311:131–140
77. Kim BO, Liu Y, Ruan Y, Xu ZC, Schantz L, He JJ (2003) Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline. Am J Pathol 162:1693–1707
78. Kim IS, Kim YT, Song HJ, Lee JJ, Kwon DH, Lee HJ, Kim MN, Yoo DS, Chang Y (2009) Reduced corpus callosum white matter microstructural integrity revealed by diffusion tensor eigenvalues in abstinent methamphetamine addicts. Neurotoxicology 30:209–213
79. Kitamura O, Takeichi T, Wang EL, Tokunaga I, Ishigami A, Kubo S (2010) Microglial and astrocytic changes in the striatum of methamphetamine abusers. Leg Med (Tokyo) 12:57–62
80. Krasnova IN, Cadet JL (2009) Methamphetamine toxicity and messengers of death. Brain Res Rev 60:379–407
81. Kuczenski R, Everall IP, Crews L, Adame A, Grant I, Masliah E (2007) Escalating dose-multiple binge methamphetamine exposure results in degeneration of the neocortex and limbic system in the rat. Exp Neurol 207:42–51
82. Kuhn DM, Angoa-Pérez M, Thomas DM (2011) Nucleus accumbens invulnerability to methamphetamine neurotoxicity. ILAR J 52:352–365
83. Langford D, Adame A, Grigorian A, Grant I, McCutchan JA, Ellis RJ, Marcotte TD, Masliah E (2003) Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J Acquir Immune Defic Syndr 34:467–474
84. Leite SC, Correa DG, Doring TM, Kubo TT, Netto TM, Ferracini R, Ventura N, Bahia PR, Gasparetto EL (2013) Diffusion tensor MRI evaluation of the corona radiata, cingulate gyri, and corpus callosum in HIV patients. J Magn Reson Imaging 38:1488–1493
85. Liu X, Chang L, Vigorito M, Kass M, Li H, Chang SL (2009) Methamphetamine-induced behavioral sensitization is enhanced in the HIV-1 transgenic rat. J NeuroImmune Pharmacol 4:309–316
86. Loftis JM, Janowsky A (2014) Neuroimmune basis of methamphetamine toxicity. Int Rev Neurobiol 118:165–197
87. Lyons A, Pitts M, Grierson J (2013) Methamphetamine use in a nationwide online sample of older Australian HIV-positive and HIV-negative gay men. Drug Alcohol Rev 32:603–610
88. Marcondes MC, Flynn C, Watry DD, Zandonatti M, Fox HS (2010) Methamphetamine increases brain viral load and activates natural killer cells in simian immunodeficiency virus-infected monkeys. Am J Pathol 177:355–361
89. Marks WD, Paris JJ, Schier CJ, Denton MD, Fitting S, McQuiston AR, Knapp PE, Hauser KF (2016) HIV-1 Tat causes cognitive deficits and selective loss of parvalbumin, somatostatin, and neuronal nitric oxide synthase expressing hippocampal CA1 interneuron subpopulations. J Neurovirol. doi:10.1007/s13365-016-0447-2
90. Marquine MJ, Iudicello JE, Morgan EE, Brown GG, Letendre SL, Ellis RJ, Deutsch R, Woods SP, Grant I, Heaton RK (2014) "Frontal systems" behaviors in comorbid human immunodeficiency virus infection and methamphetamine dependency. Psychiatry Res 215:208–216
91. Martin-Thormeyer EM, Paul RH (2009) Drug abuse and hepatitis C infection as comorbid features of HIV associated neurocognitive disorder: neurocognitive and neuroimaging features. Neuropsychol Rev 19:215–231
92. Massanella M, Gianella S, Schrier R, Dan JM, Perez-Santiago J, Oliveira MF, Richman DD, Little SJ, Benson CA, Daar ES, Dube MP, Haubrich RH, Smith DM, Morris SR (2015) Methamphetamine use in HIV-infected individuals affects T-cell function and viral outcome during suppressive antiretroviral therapy. Sci Rep 5:13179
93. McKenna BS, Brown GG, Archibald S, Scadeng M, Bussell R, Kesby JP, Markou A, Soontornniyomkij V, Achim C, Semenova S (2016) Microstructural changes to the brain of mice after methamphetamine exposure as identified with diffusion tensor imaging. Psychiatry Res 249:27–37
94. Mediouni S, Garibaldi Marcondes MC, Miller C, McLaughlin JP, Valente ST (2015) The cross-talk of HIV-1 tat and methamphetamine in HIV-associated neurocognitive disorders. Front Microbiol 6:1164
95. Minassian A, Henry BL, Woods SP, Vaida F, Grant I, Geyer MA, Perry W, Translational Methamphetamine AIDS Research Center Group (2013) Prepulse inhibition in HIV-associated neurocognitive disorders. J Int Neuropsychol Soc 19:709–717
96. Minassian A, Young JW, Cope ZA, Henry BL, Geyer MA, Perry W (2016) Amphetamine increases activity but not exploration in humans and mice. Psychopharmacology 233:225–233
97. Mitchell SJ, Morris SR, Kent CK, Stansell J, Klausner JD (2006) Methamphetamine use and sexual activity among HIV-infected patients in care--San Francisco, 2004. AIDS Patient Care STDs 20:502–510
98. Montoya JL, Cattie J, Morgan E, Woods SP, Cherner M, Moore DJ, Atkinson JH, Grant I (2016) The impact of age, HIV serostatus and seroconversion on methamphetamine use. Am J Drug Alcohol Abuse 42:168–177
99. Moore DJ, Blackstone K, Woods SP, Ellis RJ, Atkinson JH, Heaton RK, Grant I (2012) Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence. AIDS Care 24:1504–1513
100. Moran LM, Aksenov MY, Booze RM, Webb KM, Mactutus CF (2012) Adolescent HIV-1 transgenic rats: evidence for dopaminergic alterations in behavior and neurochemistry revealed by methamphetamine challenge. Curr HIV Res 10:415–424
101. Moran LM, Booze RM, Webb KM, Mactutus CF (2013) Neurobehavioral alterations in HIV-1 transgenic rats: evidence for dopaminergic dysfunction. Exp Neurol 239:139–147
102. Nath A, Schiess N, Venkatesan A, Rumbaugh J, Sacktor N, McArthur J (2008) Evolution of HIV dementia with HIV infection. Int Rev Psychiatry 20:25–31
103. Nightingale S, Winston A, Letendre S, Michael BD, McArthur JC, Khoo S, Solomon T (2014) Controversies in HIV-associated neurocognitive disorders. Lancet Neurol 13:1139–1151
104. Nordahl TE, Salo R, Natsuaki Y, Galloway GP, Waters C, Moore CD, Kile S, Buonocore MH (2005) Methamphetamine users in sustained abstinence: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry 62:444–452
105. Pantalone DW, Bimbi DS, Holder CA, Golub SA, Parsons JT (2010) Consistency and change in club drug use by sexual minority men in New York City, 2002 to 2007. Am J Public Health 100:1892–1895
106. Passaro RC, Pandhare J, Qian HZ, Dash C (2015) The complex interaction between methamphetamine abuse and HIV-1 pathogenesis. J NeuroImmune Pharmacol. doi:10.1007/s11481-015-9604-2
107. Paulus MP, Rogalsky C, Simmons A, Feinstein JS, Stein MB (2003a) Increased activation in the right insula during risk-taking decision making is related to harm avoidance and neuroticism. NeuroImage 19:1439–1448
108. Paulus MP, Hozack N, Frank L, Brown GG, Schuckit MA (2003b) Decision making by methamphetamine-dependent subjects is associated with error-rate-independent decrease in prefrontal and parietal activation. Biol Psychiatry 53:65–74
109. Perry W, Minassian A, Paulus MP, Young JW, Kincaid MJ, Ferguson EJ, Henry BL, Zhuang X, Masten VL, Sharp RF, Geyer MA (2009) A reverse-translational study of dysfunctional exploration in psychiatric disorders: from mice to men. Arch Gen Psychiatry 66:1072–1080
110. Pfefferbaum A, Rosenbloom MJ, Sassoon SA, Kemper CA, Deresinski S, Rohlfing T, Sullivan EV (2012) Regional brain structural dysmorphology in human immunodeficiency virus infection: effects of acquired immune deficiency syndrome, alcoholism, and age. Biol Psychiatry 72:361–370
111. Plankey MW, Ostrow DG, Stall R, Cox C, Li X, Peck JA, Jacobson LP (2007) The relationship between methamphetamine and popper use and risk of HIV seroconversion in the multicenter AIDS cohort study. J Acquir Immune Defic Syndr 45:85–92
112. Potash MJ, Chao W, Bentsman G, Paris N, Saini M, Nitkiewicz J, Belem P, Sharer L, Brooks AI, Volsky DJ (2005) A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and neuroinvasiveness. Proc Natl Acad Sci U S A 102:3760–3765
113. Ragin AB, Storey P, Cohen BA, Epstein LG, Edelman RR (2004) Whole brain diffusion tensor imaging in HIV-associated cognitive impairment. AJNR Am J Neuroradiol 25:195–200
114. Reback CJ, Larkins S, Shoptaw S (2003) Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care 15:775–785
115. Reid W, Sadowska M, Denaro F, et al. (2001) An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc Natl Acad Sci U S A 98:9271–9276
116. Rippeth JD, Heaton RK, Carey CL, Marcotte TD, Moore DJ, Gonzalez R, Wolfson T, Grant I (2004) Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc 10:1–14
117. Roberts AJ, Maung R, Sejbuk NE, Ake C, Kaul M (2010) Alteration of methamphetamine-induced stereotypic behaviour in transgenic mice expressing HIV-1 envelope protein gp120. J Neurosci Methods 186:222–225
118. Rosenbloom MJ, Sullivan EV, Pfefferbaum A (2010) Focus on the brain: HIV infection and alcoholism: comorbidity effects on brain structure and function. Alcohol Res Health 33:247–257
119. Sacktor N, Robertson K (2014) Evolving clinical phenotypes in HIV-associated neurocognitive disorders. Curr Opin HIV AIDS 9:517–520
120. Sacktor N, Skolasky RL, Seaberg E, Munro C, Becker JT, Martin E, Ragin A, Levine A, Miller E (2016) Prevalence of HIV-associated neurocognitive disorders in the multicenter AIDS cohort study. Neurology 86:334–340
121. Salamanca SA, Sorrentino EE, Nosanchuk JD, Martinez LR (2014) Impact of methamphetamine on infection and immunity. Front Neurosci 8:445
122. Salo R, Buonocore MH, Leamon M, Natsuaki Y, Waters C, Moore CD, Galloway GP, Nordahl TE (2011) Extended findings of brain metabolite normalization in MA-dependent subjects across sustained abstinence: a proton MRS study. Drug Alcohol Depend 113:133–138
123. Sekine Y, Ouchi Y, Sugihara G, Takei N, Yoshikawa E, Nakamura K, Iwata Y, Tsuchiya KJ, Suda S, Suzuki K, Kawai M, Takebayashi K, Yamamoto S, Matsuzaki H, Ueki T, Mori N, Gold MS, Cadet JL (2008) Methamphetamine causes microglial activation in the brains of human abusers. J Neurosci 28:5756–5761
124. Semple SJ, Patterson TL, Grant I (2004) The context of sexual risk behavior among heterosexual methamphetamine users. Addict Behav 29:807–810
125. Sharma A, Hu XT, Napier TC, Al-Harthi L (2011) Methamphetamine and HIV-1 Tat down regulate β-catenin signaling: implications for methampetamine abuse and HIV-1 co-morbidity. J NeuroImmune Pharmacol 6:597–607
126. Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, Calmy A, Chave JP, Giacobini E, Hirschel B, Du Pasquier RA (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24:1243–1250
127. Skarbinski J, Rosenberg E, Paz-Bailey G, Hall HI, Rose CE, Viall AH, Fagan JL, Lansky A, Mermin JH (2015) Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Intern Med 175:588–596
128. Soontornniyomkij V, Umlauf A, Soontornniyomkij B, Batki IB, Moore DJ, Masliah E, Achim CL (2016) Lifetime methamphetamine dependence is associated with cerebral microgliosis in HIV-1-infected adults. J Neurovirol. doi:10.1007/s13365-016-0441-8
129. Stebbins GT, Smith CA, Bartt RE, Kessler HA, Adeyemi OM, Martin E, Cox JL, Bammer R, Moseley ME (2007) HIV-associated alterations in normal-appearing white matter: a voxel-wise diffusion tensor imaging study. J Acquir Immune Defic Syndr 46:564–573
130. Stone VE, Baron-Cohen S, Knight RT (1998) Frontal lobe contributions to theory of mind. J Cogn Neurosci 10:640–656
131. Stubbe-Drger B, Deppe M, Mohammadi S, Keller SS, Kugel H, Gregor N, Evers S, Young P, Ringelstein EB, Arendt G, Knecht S, Husstedt IW, German Competence Network HA (2012) Early microstructural white matter changes in patients with HIV: a diffusion tensor imaging study. BMC Neurol 12:23
132. Taylor MJ, Schweinsburg BC, Alhassoon OM, Gongvatana A, Brown GG, Young-Casey C, Letendre SL, Grant I (2007) Effects of human immunodeficiency virus and methamphetamine on cerebral metabolites measured with magnetic resonance spectroscopy. J Neurovirol 13:150–159
133. Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L (1994) Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 367:188–193
134. Tong J, Fitzmaurice P, Furukawa Y, Schmunk GA, Wickham DJ, Ang LC, Sherwin A, McCluskey T, Boileau I, Kish SJ (2014) Is brain gliosis a characteristic of chronic methamphetamine use in the human? Neurobiol Dis 67:107–118
135. Valcour VG, Shikuma CM, Watters MR, Sacktor NC (2004) Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms. AIDS 18(Suppl 1):S79–S86
136. Var SR, Day TR, Vitomirov A, Smith DM, Soontornniyomkij V, Moore DJ, Achim CL, Mehta SR, Perez-Santiago J (2016) Mitochondrial injury and cognitive function in HIV infection and methamphetamine use. AIDS 30:839–848
137. Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, Gatley SJ, Miller E, Hitzemann R, Ding YS, Logan J (2001) Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21:9414–9418
138. Volkow ND, Fowler JS, Wang GJ, Shumay E, Telang F, Thanos PK, Alexoff D (2010) Distribution and pharmacokinetics of methamphetamine in the human body: clinical implications. PLoS One 5:e15269
139. Wang GJ, Volkow ND, Chang L, Miller E, Sedler M, Hitzemann R, Zhu W, Logan J, Ma Y, Fowler JS (2004) Partial recovery of brain metabolism in methamphetamine abusers after protracted abstinence. Am J Psychiatry 161:242–248
140. Weber E, Morgan EE, Iudicello JE, Blackstone K, Grant I, Ellis RJ, Letendre SL, Little S, Morris S, Smith DM, Moore DJ, Woods SP (2013) Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection. J Neurovirol 19:65–74
141. Wilson ME, Dimayuga FO, Reed JL, Curry TE, Anderson CF, Nath A, Bruce-Keller AJ (2006) Immune modulation by estrogens: role in CNS HIV-1 infection. Endocrine 29:289–297
142. Woods SP, Rippeth JD, Frol AB, Levy JK, Ryan E, Soukup VM, Hinkin CH, Lazzaretto D, Cherner M, Marcotte TD, Gelman BB, Morgello S, Singer EJ, Grant I, Heaton RK (2004) Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol 26:759–778
143. Yang S, Belcher AM, Chefer S, Vaupel DB, Schindler CW, Stein EA, Yang Y (2015) Withdrawal from long-term methamphetamine self-administration ‘normalizes’ neurometabolites in rhesus monkeys: a (1) H MR spectroscopy study. Addict Biol 20:69–79
144. Young JW, Minassian A, Paulus MP, Geyer MA, Perry W (2007) A reverse-translational approach to bipolar disorder: rodent and human studies in the behavioral pattern monitor. Neurosci Biobehav Rev 31:882–896
145. Zahr NM, Mayer D, Rohlfing T, Sullivan EV, Pfefferbaum A (2014) Imaging neuroinflammation? A perspective from MR spectroscopy. Brain Pathol 24:654–664
146. Zhuang W, Tang Y, Zhong N, Jiang H, Du J, Wang J, Zhao M (2016) Persistent microstructural deficits of internal capsule in one-year abstinent male methamphetamine users: a longitudinal diffusion tensor imaging study. J NeuroImmune Pharmacol. doi:10.1007/s11481-016-9673-x